Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Aims to Generate up to 80% of Revenues from Technology Licensing

  • CEO Chris Bunka says in audio interview that human study of company’s proprietary TurboCBD technology will start in April outside of North America
  • Hopes to add 6-12 more IP technology licensing contracts within year
  • Cutting-edge research designed to attract the attention of tobacco and cannabis industries

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Chris Bunka said in a recent audio interview that, although consumer products will always be important to LXRP, he estimates that up to 80 percent of its revenues could be generated through the licensing of its proprietary technology to other companies (http://cnw.fm/yT2HS).

LXRP is a British Columbia, Canada-based bioscience company that is a drug delivery platform innovator. The company has developed its patented DehydraTECH™ delivery technology platform, which it out-licenses to promote healthier ingestion methods and lower overall dosing.

Bunka said that LXRP believes that 6-12 more licensing contracts will be signed this year, both generating more revenue for the company and building greater shareholder value. “We’ve only just graduated from the demonstration phase,” he explained in the interview.

“The latest contracts are typically six figure contracts in the first year and potentially seven figure contracts over the life of the contracts,” Bunka added. “They’re becoming bigger.” The company sees a potential game changer for itself in three new sets of studies and believes that each could be material to the valuation of the company.

The first is a completed study of the company’s proprietary DehydraTECH in the form of a topical cream for the absorption of cannabidiol (CBD) through human skin (http://cnw.fm/Lc5dU). LXRP said that results showed significant increases in quantity and speed of CBD absorption through the skin when compared to other formulations.

The second is a lab animal study that tests nicotine absorption. Using lab rats, the study measures gastrointestinal distress (http://cnw.fm/d7uXC). It will take blood and tissue samples at pre-prescribed time intervals to measure nicotine absorption. It will test LXRP’s ‘Trojan horse’ technology that may hide it from a negative response triggered by the body, Bunka said. An end goal is to bypass liver absorption and help avoid kidney and liver diseases associated with some of these substances by using LXRP technologies.

The third is a clinical human study first started with a Canadian University.  Now, it has been moved out of North America into another institution, and the study’s initiation is imminent, he added. The study is on the cardiovascular and health effects of the company’s TurboCBD™ (http://cnw.fm/e6HIm). Bunka at the time said that the study would permit LXRP to custom design products that would increase the performance its technology already offers to customers.

“That study is now back on track. We expect it to begin in the month of April in a different location,” Bunka noted.

He added that all three studies, or any one of them, could mean a major change for the company, as its IP and studies attract increased interest from both the tobacco and cannabis industries. Lexaria has developed cutting-edge technologies with commercial application, he said in the interview.

“Those three studies, each one of those, has the potential to be a real game changer in the valuation of the company,” Bunka said.

For more information, visit the company’s website at www.LexariaBioscience.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) Readies Niche Products for Legal Cannabis Industry

  • Spending on legal cannabis worldwide expected to hit $57 billion by 2027
  • Canadian government preparing to legalize cannabis-infused edibles and beverages by mid-2019
  • Investments into cannabis-related companies topped $1.2 billion over first five weeks of 2018

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P), a vertically-integrated cannabis company with strategic investments in proven, revenue-generating businesses, is building a diversified portfolio that includes marketing a wide range of high quality, medicinal grade cannabis products with tremendous promise for both human and veterinary use. Liberty Leaf and its wholly owned subsidiary, North Road Ventures, recently signed an agreement with Cannabis Compliance Inc. (“CCI”) to establish Good Manufacturing Practice (GMP)-compliant processes and procedures in producing its finished products (http://cnw.fm/k9W56).

“We are extremely excited to be working with CCI in establishing GMP manufacturing capabilities in-house,” Robert Jackman, scientific project manager/fulfillment for Liberty Leaf, stated in a news release. “This opens the door for North Road to obtain industry certification and regulatory authorization and/or licensing, as needed. It facilitates the manufacture and sale of a wide range of medicinal-quality products for both human and veterinary use – not just cannabis and cannabis-containing finished products.”

According to Arcview Market Research and its research partner BDS Analytics, spending on legal cannabis worldwide is projected to hit $57 billion by 2027, as noted in an article published by Forbes (http://cnw.fm/88xXT). The adult-use recreational market is expected to generate 67 percent of those dollars, with medical marijuana taking up the remaining 33 percent. Cannabis buyers in North America, who are currently spending a little more than $9 billion, are expected to lay down $47.3 billion by 2027, the article states.

In Canada, the government’s decision to legalize recreational cannabis for adult users by mid-2018 will soon be followed by the prospect of additional profits in cannabis-infused edibles and beverages as these items become legal in the summer of 2019 (http://cnw.fm/pc0xM). Medical cannabis has been legal in Canada since 2001. Allowing edibles and cannabis-infused beverages is expected to generate an exceptional amount of interest from the public, according to a recent survey by Dalhousie University, a public research university in Canada.

“Curiosity seems to be driving consumers to want to try a food product, an edible, and the number one choice is bakery goods,” Dr. Sylvain Charlebois, the study’s lead author, said in an interview with CTVNews.ca (http://cnw.fm/V8FKk). The survey of 1,087 people found that 46 percent of Canadians would try cannabis-infused food products such as baked goods, oils and spices if they were commercially available.

Liberty Leaf President and Director William Rascan said that working with Cannabis Compliance to meet Canada’s strict GMP requirements for commercial production ensures that North Road will consistently manufacture safe, high quality finished cannabis-related products. North Road’s distribution strategy also includes a unique approach not yet seen in the cannabis industry, Rascan added.

“North Road plans to make available to both pharmacies and licensed retailers our exclusive medicinal-quality cannabis, cannabis-related products and racking jobber service,” Rascan said. “The ability for us to expand on our model by including Natural Health Products (NHPs) for human and veterinary use as well as cosmetics/beauty products, topicals, concentrates, foods/edibles and other high-quality products for distribution holds tremendous growth potential for our company.”

Investors continue to seek out and support cannabis companies – to the tune of more than $2.1 billion over the first five weeks of 2018, according to the Viridian Cannabis Deal Tracker, which tracks capital raises and M&A activity in the cannabis industry (http://cnw.fm/o7l4L). The demand for medical, recreational and cannabis-infused products is projected to continue its upward trajectory as more states in the U.S. begin to legalize some aspect of the highly regulated plant and Canada’s new laws take effect (http://cnw.fm/0hZMx).

For more information, visit the company’s website at www.LibLeaf.ca

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Continues to Advance its Agenda

  • Owns worldwide rights for patented formulations and drug delivery technologies
  • Develops and commercializes therapeutic pharmaceuticals and nutraceuticals
  • Strategic agenda to become one of world’s only vertically integrated cannabis biotechs

With worldwide rights for unique drug delivery platforms in place, Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) is rapidly building a disruptive, vertically integrated biotechnology company. Advancing this agenda, the company recently announced that it has retained Cannabis Compliance Inc. to submit an application to Health Canada for a dealer’s license on behalf of Pivot’s acquisition target, Agro-Biotech Inc. (http://cnw.fm/0K5Xn).

In February, Pivot announced that its entry into a letter of intent for the proposed acquisition of licensed cannabis producer Agro-Biotech (http://cnw.fm/cvP6W), which operates a fully licensed indoor hydroponic cannabis production facility that’s on track to expand its capacity 10,000 kg per year by the end of this year. Upon completion of the proposed acquisition, the dealer’s license will enable Pivot (through Agro-Biotech) to conduct research and store cannabis derivatives that are not currently covered under the Access to Cannabis for Medical Purposes Regulations.

With the acquisition of Agro-Biotech, Pivot Pharmaceuticals will control the entire manufacturing process from seed to medical derivatives and capture margins along the entire supply chain. The dealer’s license will move Pivot another step closer to becoming one of the only vertically integrated cannabis biotech companies in the world. Pivot is already a differentiated player in the Canadian cannabis industry with its unique approach to enhanced dosing and bioavailability of cannabinoids, and the company’s position in the market will only be bolstered by the acquisition.

Pivot Pharmaceuticals has assembled cutting-edge drug delivery technologies that assist both effectiveness and efficacy of medicinal cannabinoids and have potential applications across other drug categories. Pivot’s patent pending topical transdermal drug delivery technology platform, BiPhasix™, has been shown to significantly enhance the bioavailability of various drugs, leading to improved clinical outcomes. The company also acquired worldwide rights to Solmic Solubilisation Technology Platform, which allows active ingredients to become water-soluble without changing their composition or nature, significantly enhancing drug uptake.

With proven pharmaceutical and patented formulation and delivery technologies, Pivot is well positioned in an important, growing vertical of the cannabis industry and represents a compelling opportunity in the biotechnology sector. This latest announcement by Pivot enhances the opportunity.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Global Payout Inc. (GOHE) Subsidiary’s Public Initial Blockchain Offering Showcases Company’s Fintech Capabilities

  • SEC-regulated offering of digital tokens
  • Balance sheet funding program for fintech investments
  • Issuer (MoneyTrac subsidiary) focused on fintech for cannabis industry

With a public initial blockchain offering (“PIBCO”) now underway, Global Payout Inc. (OTC: GOHE) is showcasing its innovative prowess. A PIBCO is similar to an initial coin offering, except that the coins or tokens involved are treated as securities under federal laws. As a result, the rights and benefits represented by those digital assets are subject to SEC rules. Under the PIBCO, Global Payout’s majority-owned subsidiary, MoneyTrac Technology, Inc. (“MTRAC”), will offer tokens that provide share warrants of MoneyTrac Technology Inc. The company expects that the balance sheet funding program thus created will yield returns to token holders within two years.

Initial coin offerings (“ICOs”) have had enormous success in 2017. The 10 largest were able to raise over one billion dollars, according to Bloomberg (http://cnw.fm/0CBb2). Filecoin, a data storage network, raised $257 million, while Tezos, which has developed its own secure blockchain infrastructure, raised $232 million. Amazingly, there were over 200 ICOs in 2017, some of which, very likely, were of dubious value.

This snake oil environment has prompted Pegasus Fintech to develop a process for public companies to initiate regulatory-compliant ICOs, referred to as public initial blockchain offerings to distinguish them from their unregulated brethren. Pegasus Fintech, Inc. is an innovative blockchain and token accelerator focused on delivering solutions in the financial services, blockchain and emerging cryptocurrency market sectors. With the PIBCO being subject to some SEC oversight, investor risk may be mitigated.

Compliance with federal securities laws is an essential requirement when funds are raised in the capital markets. Generally, any offer or sale of a security must either be registered with the SEC or meet an exemption. Regulation D, under the Securities Act of 1933, provides a number of exemptions from the registration requirements. However, notification of the issue and sale of the securities must be given to the SEC.

The MTRAC offering has been made under Rule 506(c) of Regulation D, which limits participation to “accredited investors” (http://cnw.fm/w7pJM). An individual is considered an “accredited investor” if he or she has earned income that exceeded $200,000 (or $300,000 together with a spouse) in each of the prior two years and reasonably expects the same for the current year or has a net worth over $1 million, either alone or together with a spouse (excluding the value of the person’s primary residence and any loans secured by the residence (up to the value of the residence)).

The funds raised in this offering will, most likely, be invested in a fashion similar to some recent business deals. For example, Global Payout’s MoneyTrac subsidiary has acquired a majority stake in PotSaver, a periodical that provides listings on discounted cannabis-related products for local dispensaries and shops. Global Payout’s MoneyTrac division is aiming to become the most recognized brand for financial technology solutions in the cannabis industry. In addition, MTRAC has entered into an exclusive partnership with GreenBox POS, LLC (“GBOX”), a blockchain company, to provide strategic sales and marketing resources. MTRAC is set to launch GBOX services in the U.S., Canada and Mexico in April 2018. GBOX’s customized payment solutions, electronic modifications and custom-built blockchain kiosk machines fall in perfectly with MTRAC’s mission of ‘Banking the Unbankable’.

Global Payout has certainly come a long way since its inception in 2009. The company quickly became a leading provider of customized prepaid payment solutions for domestic and international organizations that distributed money across the globe. In 2014, it introduced its first online payment platform, called the Consolidated Payment Gateway (“CPG”), which allowed enterprise clients to transfer money to international bank accounts, mobile accounts and prepaid card accounts. Global Payout’s CPG has become the foundation for the introduction of its new, state-of-the-art fintech payment system in 2017, for both online and mobile applications that allow account holders access to an expanded suite of financial services. A look at how the company is applying blockchain for smart solutions is available in a recent Audio Press Release (http://cnw.fm/fNfa0).

For more information, visit the company’s website at www.GlobalPayout.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Secures Australian Importation Permit in Support of Research into Sol-gels

  • Research will be conducted at PACE, a leading pharmaceutical research center in Australia
  • PreveCeutical’s unique technology promises to be the first FDA-approved, CBD-based nose-to-brain delivery system using a Sol-gel platform
  • Groundbreaking technology outstrips the benefits of any other delivery mechanism

On March 13, 2018, PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) and Aurora Cannabis Inc. (OTCQB: ACBFF) (TSX: ACB) (FSE: 21P) announced that they had received three permits for the importation of cannabis plant material into Australia for research purposes. The permits were granted by the Australian Government’s Department of Health, allowing shipment from Canada by Aurora Cannabis Enterprises Inc., a wholly owned subsidiary of Aurora Cannabis Inc.

Preveceutical’s research program will be conducted at the University of Queensland’s Pharmacy Australia Centre of Excellence (“PACE”), a leading center for pharmaceutical research, education and commercialization. PACE has been granted the permits to import the dried cannabis flower and oils that will be used in the company’s innovative soluble gel (Sol-gel) drug delivery research program. It will be led by Dr. Harendra Parekh, chief research officer of PreveCeutical. The research team will test a range of cannabis strains to determine candidacy for the development and commercialization of cannabinoid-based Sol-gels.

The primary goal of the research program is to develop a nose-to-brain delivery system that will increase the bioavailability of active drug ingredients. The focus of the research is to apply Sol-gel technology to develop cannabinoid-based therapies for the relief of symptoms associated with pain, inflammation, seizures and neurological disorders. In a news release detailing the announcement, Stephen Van Deventer, chairman and CEO of PreveCeutical, said, “We are extremely excited to receive the Permits, allowing us to further our Sol-gel research program with the high quality cannabis products provided by Aurora. The goal of the Program is to cultivate a range of therapies that will benefit people with ailments such as epilepsy, pain and inflammation, safely and economically.”

“We see an important market for cannabis-based products that are more narrowly targeted at specific therapeutic areas but that are higher value add and being involved with initiatives such as PreveCeutical’s is part of our strategy to gain access to these types of products,” added Terry Booth, CEO of Aurora.

PreveCeutical believes that its cannabinoid-based nose-to-brain delivery technology, using a Sol-gel platform, will be the first to gain Food and Drug Administration approval. Its water soluable, alcohol free nasal formulation which will be developed for use by adults, children and people of certain beliefs.

PreveCeutical’s groundbreaking Sol-gel delivery system displays significant benefits over other contemporary delivery systems. It bypasses first pass metabolism in the stomach, intestines and liver, exhibiting a dramatic improvement in bioavailability, even compared to nasal sprays and alternative delivery mechanisms. Unlike other delivery systems, PreveCeutical’s Sol-gel delivery technology enables ease of application and provides long-lasting effects, all while eliminating negative side effects.

This latest research initiative comes on the back of established innovative solutions for preventive and curative therapies. The company’s first product, CELLB9®, is a Caribbean blue scorpion venom-based product that has been successfully marketed and distributed worldwide. PreveCeutical is currently in the development phase of a product based on this venom for the treatment, regulation and prevention of cancer progression. The company is also developing solutions based on the peptides derived from Caribbean blue scorpion venom for pain management, cancers, cardiovascular conditions, metabolic disorders and infectious diseases.

For more information, visit the company’s website at www.PreveCeutical.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

ChineseInvestors.com, Inc. (CIIX) CEO Discusses the Company’s Future on MoneyTV

Warren Wang, founder and CEO of ChineseInvestors.com (OTCQB: CIIX), was recently interviewed on MoneyTV with Donald Baillargeon. The company, in addition to being a leader in education products and services for the Chinese-speaking community in North America and elsewhere, has recognized and seized the opportunity in the growing cannabis industry. With a focus on cryptocurrency and financial education, as well as a new private company spinoff of its hemp assets, CIIX is a company to watch. Wang spoke of upcoming changes in both the cannabis and cryptocurrency markets.

Anticipating the potential revenue of the company’s hemp assets for the 2018-2019 fiscal year in the range of $1 million to $4 million, Wang spoke of the spinoff of CIIX’s hemp assets into a private company as a positive and exciting move. The American cannabis market continues to grow, though still divided, and the newly formed spinoff company is set to achieve strong revenues with the legalization of cannabis in Canada this summer. CIIX’s hemp products can be found on Amazon. In the next six to eight months, the products will be rebranded, with the product line being expanded on Amazon and the price potentially dropping as hemp products become more mainstream in America.

The formal spinoff of CIIX’s hemp assets will occur on May 31, 2018, and investors will receive stock dividends. The new company will include wholly owned foreign enterprise CBD Biotechnology Co., Ltd. and U.S.-based wholly owned subsidiaries Hemp Logic, Inc. and ChineseHempOil.com, Inc. Shareholders have the option to exchange four shares of CIIX common stock for one share in the new company (http://cnw.fm/Z4wAo). The new company is expected to be brought to the public market, through either OTC or Canadian exchange, in the next 10-18 months.

This spinoff will allow CIIX to focus on financial and investment education covering a number of areas, including cryptocurrency. CIIX provides real-time reliable market information to investors, equipping them to make informed investment decisions. As cryptocurrency becomes an emerging asset, CIIX has positioned itself to be the leading educational source for the Chinese-speaking community to answer investor questions on what cryptocurrency is, how to trade it, where to store wallets, the prevalence of ICOs and much more. There is a great deal of education needed around the tech parts of cryptocurrency, and CIIX is focused on providing the education and confidence that the growing Chinese-speaking investor community is actively seeking.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Medical Cannabis Payment Solutions’ (REFG) Green is Designed to Grow

  • Proprietary payment platform customized for legal cannabis merchants makes it a gateway to the industry for electronic money transactions
  • CEO Jeremy Roberts says that Green platform takes state-sanctioned cannabis into the 21st century of electronic banking and financial services
  • Green platform offers ease of cash management to merchants while enabling consumers and patients to purchase electronically, even with cryptocurrency

Medical Cannabis Payment Solutions’ (OTC: REFG) Green platform, a top tier digital payment processing system, is designed to bring legalized cannabis and its cash management for licensed merchants and dispensaries into the world of digital financial services.

“What we’re launching is the very literal cure for the banking nightmare cannabis establishments face,” Jeremy Roberts, CEO of REFG, stated in a news release (http://cnw.fm/od3rP). “This checks every box, from regulatory compliance, security, affordability, ease of use, integration — you name it, we’ve responded.”

Among its key advantages are the money management system and the simple signup feature for consumers. Not only is it FinCEN-compliant, Green offers both merchants and customers an enticing platform to manage money for sellers and financial services for buyers.

For merchants, it can be integrated with most any existing point-of-sale system. Recurring billing for consumers can be set up, as well as money management features such as payroll. Green also offers ease of digital payments, tracking of customer sales and even internal payments. For consumers, the platform is easy to join for purchasing legalized cannabis products from licensed merchants or dispensaries, even using cryptocurrency, if desired. REFG has partnered with First Bitcoin Capital Corporation to ensure acceptance of virtual currencies (http://cnw.fm/MeyI7).

To create loyalty and drive repeat purchases, REFG can even brand its Green cards with the merchant’s name and logo.

For more information, visit the company’s website at www.MedicalCannabisPaymentSolutions.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Global Hemp Group, Inc. (CSE: GHG) (FRA: GHG) (OTC: GBHPF) Completes $1.5 Million Private Placement

  • Proceeds to be used for development of new cultivation and processing project in New Brunswick
  • A boost to operating capital
  • Canada plans to legalize the extraction of cannabinoids from hemp in mid-2018
  • Market for hemp CBD products is predicted to grow to $450 million by 2020

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF), a company focused on the cultivation of hemp and cannabinoid extraction for both domestic and international markets, announced on March 7, 2018, that it had closed a non-brokered private placement, consisting of 12.5 million units at a price of $0.12 per unit, to raise $1.5 million (http://cnw.fm/DK0u6). Each unit comprises one common share of the company and one common share purchase warrant. The warrant entitles the holder to purchase one common share at a price of $0.15 for a period of five years from closing. No finder’s fee was paid on this placement, and all securities issued are subject, in accordance with securities laws, to a four-month plus one day holding period from date of issue.

Global Hemp Group intends to use the proceeds for several purposes. Firstly, the capital will be used to fund the development of its New Brunswick hemp cultivation and extraction project. In conjunction with its joint venture partner, Marijuana Company of America (OTC: MCOA), Global Hemp Group completed its industrial hemp trials in northeast New Brunswick at the end of 2017. This marked the first harvest of hemp on the Acadian peninsula in 20 years. The partners have recruited hemp farmers to work 125 acres in 2018 and plan to increase the area under cultivation to over 1,000 acres within three years. Global Hemp will supply its considerable technical and management expertise for this project.

The proceeds will also be used to fund due diligence on potential acquisitions, namely in the State of Oregon, where Global Hemp Group is contemplating buying land for hemp cultivation and cannabinoid extraction. The funds will also be used to bolster the company’s working capital. Company insiders subscribed for a total amount of $371,542, representing 24.8 percent of the private placement.

Founded in 2014, Global Hemp Group is building a strategic portfolio of hemp-based companies to provide its global customer base with a consistent supply of high-quality hemp-derived products. It intends to leverage the huge market potential of hemp products to deliver significant ROI to its shareholders. The number of products that can be manufactured from the hemp plant is vast. It can be used to provide food, clothing, building materials, fuel and medicine. Additionally, its use for the development and production of cannabidiol (CBD)-based medical products has immense market potential. In the future, Global Hemp Group intends to establish several Hemp Agro-Industrial Zones (HAIZ) for the development of industrial hemp cultivation and processing facilities. The company plans to achieve the development of this concept through joint ventures, partnerships or acquisitions of companies involved in the farming, processing, manufacturing and distribution of hemp products.

The market for CBD-based medical products has witnessed a huge surge over the last year, and it is expected to grow at a CAGR of more than 39 percent over the next four years. The Hemp Business Journal (http://cnw.fm/0D2nh) forecasts that the CBD market will grow to over $2 billion by 2020, with $450 million attributed to hemp-based cannabinoid medical products.

For more information, visit the company’s website at www.GlobalHempGroup.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Earth Science Tech, Inc. (ETST): Transparency, Scientific Research and Future Products

  • Received grant from Government of Québec through Canno Inno Laboratories subsidiary
  • Canna Inno Laboratories enhances collaboration between the company’s resources in Canada and the U.S. while providing access to grants
  • Sound scientific research and transparent studies

Earth Science Tech, Inc. (OTC: ETST), a Florida-based biotechnology company focused on cannabis, industrial hemp and cannabinoid research and development for nutraceuticals, pharmaceuticals and medical devices, announced last week that its subsidiary, Canna Inno Laboratories Inc., has received a grant from the Government of Québec for innovation in the pharmaceutical industry. ETST plans to apply for additional funding under Canada’s Scientific Research and Experimental Development Tax Credit program (http://cnw.fm/Q2v2O).

Earth Science Tech formed Canna Inno Laboratories, Inc. in 2017. Strategically headquartered in Montreal, Quebec, it allows Earth Science Tech access to Canadian government and private grants offered to companies for innovation in the pharmaceutical industry. The awarded grant will support the pre-launch process of Earth Science’s three CBD-based products. These nutraceutical products aim to prevent common causes of cancer and help reduce occurrence rates. The pre-launch process includes a series of pre-clinical in vitro trials to fight breast cancer and neurodegenerative disorders. Once complete and patent pending, these high-grade hemp CBD oil products will be commercialized as nutraceuticals and provide alternative natural treatment solutions.

Through the in vitro study with the University of Central Oklahoma and DV Biologics, ETST has provided results that confirm the positive effect of its CBD on breast cancer, immune cell function and human brain cells. The goal of ETST is to discover solutions for conditions that currently have no effective treatment, targeting diseases in which the benefits of CBD have already been demonstrated by researchers worldwide. ETST seeks to increase the effectiveness of cannabinoids and/or CBD and thereby improve treatments for different diseases. The company focuses on providing sound scientific research and transparency on the progression of studies done on its highest quality and purity, full spectrum high-grade hemp CBD products.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) Finding Ever-Growing Ways to Administer Cannabis Benefits

  • Pivot Pharmaceuticals developing disruptive formulations for cannabis-infused markets
  • Company’s goal is to strengthen dosage predictability and improve product stability
  • Recent acquisitions and planned acquisitions give Pivot vertical position in multi-billion-dollar industries

Despite recent setbacks to efforts seeking broader marijuana legalization in North America (http://cnw.fm/zM2Mc), the tide of social preferences for cannabis availability, even in recreational applications, continues to advance (http://cnw.fm/tT62e). Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) is helping to advance efforts to legitimize the drug’s use, both in medicinal and recreational settings, by pursuing ever-increasing methods for consuming cannabis’s derivatives in quantities with predictable outcomes.

“Pivot’s goal is to increase cannabinoid bioavailability, drug release rates and improve product stability, and consumers should be able to confidently take correct and accurate doses to help meet their health and wellness needs,” Joseph Borovsky, Pivot’s vice president of product formulation, stated in a recent news release (http://cnw.fm/ji5nV).

The company has filed continuation patents to maintain its impetus in making cannabis available through powdered formulations that can be combined with existing products in the food and beverage market. That includes health and wellness products such as natural sleep-aids, cold medications and vitamins.

On March 6, Pivot Pharmaceuticals announced its acquisition of Thrudermic, LLC, a North Carolina company invested in a transdermal lipid-based nano-dispersion technology to make cannabis formulations available through external delivery. Thrudermic has filed three new patent applications for Pivot related to better formulation and delivery of its product as the company pursues new routes of drug administration.

Pivot’s acquisition of California’s ERS Holdings, LLC in February not only strengthened its options for enhanced health and wellness products; the move gave the company added visibility to beverage makers such as beer companies working to mitigate a potential decline in profits as their customers divert discretionary income from alcohol consumption to cannabis consumption.

“The (Ready-To-Infuse-Cannabis technology) family of patents will be transformational for the food and beverage industry. Based on our interaction with key players in the beverage market, we anticipate that there will be a significant substitution in consumer choices towards cannabis infused drinks. With this acquisition, we have positioned Pivot to be at the forefront of this enormous new market,” Pivot CEO Patrick Frankham stated in a news release about the acquisition (http://cnw.fm/1xDEK).

The company has also announced plans to acquire Agro-Biotech, a Quebec-based Canadian-licensed cannabis producer (http://cnw.fm/av6uC). Agro-Biotech operates a licensed hydroponic cannabis production facility that can turn out 10,000 kilograms per year, giving Pivot a source for its products as it strives to achieve a stronger vertical position in the industry for cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC).

An agreement between Pivot and Germany’s Solmic Research GmbH gave the company rights to technology designed to give cancer patients relief from vomiting, nausea, neutropenia and anemia during chemotherapy treatment. Those side effects trouble an estimated 70 to 80 percent of chemotherapy patients and often lead to the discontinuation of treatment before the illness has been completely addressed, according to Transparency Market Research (http://cnw.fm/1N15u). Cannabis’s therapeutic abilities are expected to help it grow into a $55.8 billion market by 2025, according to a 2017 report by Grand View Research (http://cnw.fm/F3jWv), and the cancer supportive care products market is expected to reach $29.87 billion by 2021.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net